Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

Data ReadoutpositivelitifilimabPositive

AI Analysis

Summary

Biogen announced positive 52-week Phase 2 data for litifilimab in cutaneous lupus erythematosus, demonstrating rapid and durable improvements in skin disease activity. The results represent the longest dataset for the drug and support its potential as a first-in-class therapy in this indication.

Clinical Trial Data

Phase

Phase 2/3

Primary Endpoint

Met

Outcome Details

52-week Phase 2 data showed continued clinical improvements in skin disease activity through Week 52, with rapid onset of treatment effect as early as four weeks in participants who switched from placebo to litifilimab at Week 24

Importance:7/10

Sentiment:

0.80

Phase 2 datacutaneous lupus erythematosusdermatologyfirst-in-classclinical trial resultspositive efficacy data

Related Companies

$BIIB

Read the original article

Published by GlobeNewswire Clinical Studies on October 2, 2026 3:20 PM

Read Original